ArticlePostepy w kardiologii interwencyjnej = Advances in interventional cardiology2026
Prognostic value of the hemoglobin-albumin-lymphocyte-platelet (HALP) score for long-term mortality after transcatheter aortic valve implantation.
Article in Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Transcatheter aortic valve implantation (TAVI) is the treatment of choice for severe aortic stenosis in elderly and high-risk patients; however, long-term mortality remains substantial. Conventional surgical risk scores show limited prognostic performance in this population, in whom frailty and impaired nutritional and inflammatory status are common. The hemoglobin-albumin-lymphocyte-platelet (HALP) score integrates these domains, but its prognostic value in TAVI has not been established. Aim: To evaluate whether the preprocedural HALP score predicts long-term all-cause mortality after TAVI. Material and methods: This retrospective single-center study included 785 consecutive patients who underwent TAVI between January 2018 and January 2024. HALP scores were calculated from routine laboratory parameters. Clinical, echocardiographic, and procedural data were collected. Independent predictors of mortality were assessed using Cox regression analysis. The optimal HALP cut-off was determined by maximally selected rank statistics, and survival was analyzed using Kaplan-Meier analysis. Results: During a median follow-up of 21.8 months, 62 (8%) patients died. Non-survivors had significantly lower HALP scores and a higher prevalence of chronic kidney disease and atrial fibrillation. In multivariable analysis, lower HALP scores independently predicted mortality (HR = 0.94; 95% CI: 0.91-0.98; Conclusions: Preprocedural HALP score is an independent predictor of long-term mortality after TAVI and may aid preprocedural risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.